Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
复制标题
DOI：
10.1093/jtm/taab083
复制
发表时间：
2021-10-11
影响因子：
25.7
通讯作者：
Bertollini R
中科院分区：
文献类型：
--
作者：
Abu-Raddad LJ;Chemaitelly H;Yassine HM;Benslimane FM;Al Khatib HA;Tang P;Malek JA;Coyle P;Ayoub HH;Al Kanaani Z;Al Kuwari E;Jeremijenko A;Kaleeckal AH;Latif AN;Shaik RM;Abdul Rahim HF;Nasrallah GK;Al Kuwari MG;Al Romaihi HE;Al-Thani MH;Al Khal A;Butt AA;Bertollini R
各国推广2019冠状病毒病（Covid-19）疫苗接种的战略各不相同。一个关键问题是，在疫苗供应有限和发病率高的情况下，推迟接种第二剂疫苗，以便在最短时间内为最多的人接种疫苗，是否可以比目前在第一剂后不久接种第二剂疫苗的方案避免更多的疾病病例、住院和死亡。最近在卡塔尔报道了BNT162b2（辉瑞- biontech）疫苗对抗严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）的有效性，重点是在第二剂后14天完成接种的个人。在此，我们对首次接种后疫苗保护作用如何逐周发展进行了随访分析。SARS-CoV-2的数据取自卡塔尔全国数字卫生信息平台。该平台拥有国家集中的SARS-CoV-2数据库，其中包含自疫情开始以来的所有疫苗接种记录、聚合酶链反应（PCR）检测以及COVID-19住院和死亡情况。1该研究于2021年2月1日至3月31日进行，这是快速大规模扩大疫苗接种规模的时期。采用检测阴性病例对照研究设计评估疫苗有效性。病例和对照组按年龄、性别、
Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of people in the shortest time, in situations of limited vaccine supplies and high incidence, could avert more disease cases, hospitalizations and deaths than the current protocol of a second dose shortly after the first dose. BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Qatar was recently reported with focus on individuals who completed 14 days after the second dose. 1 Here, we provide a follow-up analysis of how vaccine protection develops week-byweek after the first dose.Data for SARS-CoV-2 were extracted from Qatar’s nationwide digital-health information platform. The platform hosts the national centralized SARS-CoV-2 databases that captured all vaccination records, polymerase chain reaction (PCR) testing, and COVID-19 hospitalizations and deaths since epidemic start. 1 The study was conducted from 1 February to 31 March 2021, the period of rapid mass vaccination scale-up. Vaccine effectiveness was estimated using the test-negative case–control study design. 2 Cases and controls were matched one-to-one by age, sex,
影响因子：
5.5
作者：
Jackson, Michael L.;Nelson, Jennifer C.
通讯作者：
Nelson, Jennifer C.